Impact of PET-CT on initial staging and treatment of breast cancer

Sachelarie, Irina; Kerr, Keith M.; Boolbol, Susan K.; Gettinger, Scott; Blum, Ronald H.

doi:10.1200/jco.2005.23.16_suppl.684

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whole body 18 FDG PET-CT is routinely utilized as an investigative modality for staging and metastatic workup in most gastrointestinal malignancies, including esophageal, gastric, and colorectal cancers. 21 Despite its widespread use in staging, response assessment, and surveillance in cases of GBC, it is still not regarded as a standard of care investigation in this particular disease. 22 23 Many studies have employed the utility of PET-CT as a metastatic tool to identify lymph nodal and distant metastases and upstage the patients prior to radical surgery while comparing it in this role to contrast-enhanced computed tomography (CECT) abdomen.…”

Section: Discussionmentioning

confidence: 99%

Utility of 18-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG PET-CT) in Gallbladder Cancer: Experience from a Tertiary Care Hospital

Bisht,

Lohia,

Singh

et al. 2023

World J Nucl Med

View full text Add to dashboard Cite

Introduction Gallbladder cancer (GBC) is one of the most common and aggressive malignancies of the Indo-Gangetic plains. Despite its widespread use in GBC cases, the role of 18-flurodeoxyglucose positron emission tomography-computed tomography (18FDG PET-CT) in the management of this disease is not well defined. In our study, we present the practice trends of the utilization of this investigative modality in our hospital and its benefits in aiding diagnosis, staging, and surveillance for recurrence. Materials and Methods All cases of suspected and biopsy-proven GBCs who underwent PET-CT at our institute between 2016 and 2019 were retrospectively evaluated for the indication of PET-CT testing and its impact on the management of the case. The indications were classified into three categories: (i) staging and metastatic workup, (ii) response assessment post-chemotherapy, and (iii) post-therapy surveillance of patients. Results A total of 79 PET-CT scans were carried out during the study period. PET-CT was used for less than one-third of the total patients of GBC presenting at our center. Initial staging and workup (49%) was the most common indication followed by surveillance (28%) and response assessment (23%). PET-CT had a substantially better sensitivity in detecting distant metastases compared to conventional imaging in both initial workup and during follow-up. PET-CT provided additional information in 42% scans that led to change in the management of the patient. As a response assessment tool PET-CT aided not only in evaluating efficacy of therapy but also for documenting progressive disease for patients on therapy. Conclusion PET-CT is a valuable tool to not only rule out metastatic disease while selecting patients for surgery but also for post-therapy surveillance for recurrence in patients of GBC. Larger prospective studies may help in finally elucidating the exact role of PET-CT in this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Utility of 18-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG PET-CT) in Gallbladder Cancer: Experience from a Tertiary Care Hospital

Bisht,

Lohia,

Singh

et al. 2023

World J Nucl Med

View full text Add to dashboard Cite

show abstract

“…10). The synthesis of the hydrophilic carboxylic acid compound 17 (logD / logP: -0.50 / 3.06 calculated by ACD/LogD Suite) was characterised by high radiochemical yields (50-60% EOB) and moderate specific activities (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26) GBq/ mol EOS). Derivative 17 was tested in in vitro gelatin degradation assays and showed IC 50 -values in the nanomolar range (MMP-2: 110 nM; MMP-9: 200 nM).…”

Section: Radiolabelled Mmpis: Synthesis In Vitro and In Vivo Evaluationmentioning

confidence: 99%

“…These combine high resolution morphological imaging with sensitive molecular imaging and are expected to significantly improve diagnostic capabilities in different clinical fields [7][8][9][10][11][12][13][14][15][16][17]. Similar advances have been made in the technical design of dedicated small animal PET and SPECT tomographs designed among other things for the evaluation of new radiotracers in different animal models [18][19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET

Wagner

Breyholz²,

Faust³

et al. 2006

CMC

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) are a family of zinc- and calcium-dependent secreted or membrane anchored endopeptidases. MMPs are involved in many physiological processes but also take part in the pathophysiological mechanisms responsible for a wide range of diseases. Pathological expression and activation of MMPs are associated with cancer, atherosclerosis, stroke, arthritis, periodontal disease, multiple sclerosis and liver fibrosis. Thus, noninvasive visualisation and quantification of MMP activity in vivo are of great interest in basic research and clinical application. This can be achieved by scintigraphic molecular imaging techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) provided suitable radiolabelled tracers exist, e.g. radioactive inhibitors of matrix metalloproteinases (MMPIs). The approach to monitor MMP activity in vivo using radiolabelled small molecule inhibitors suitable for SPECT and PET is summarised in this review. Briefly, latest advances in scintigraphic imaging are introduced and followed by a report about the enzyme class of MMPs. The involvement of MMPs in cancer and atherosclerosis is exemplified and small molecule MMPIs are classified. Subsequently, the development of radiolabelled small molecule MMPIs, their synthesis and in vitro and in vivo evaluation is reviewed. Finally, an outlook on the clinical potential of labelled MMPIs in diagnostic algorithms is given.

show abstract

A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors

Kalykaki

Vamvakas²,

Agelaki³

et al. 2006

Oncology

View full text Add to dashboard Cite

Purpose: The study aimed to determine the maximum tolerated doses (MTDs) and identify the dose-limiting toxicities of the biweekly administration of pemetrexed plus gemcitabine in patients with solid tumors. Patients and Methods: Patients with advanced malignancies were treated with escalated doses of gemcitabine and pemetrexed (starting doses 1,250 and 300 mg/m², respectively) both given on days 1 and 15 in cycles of 4 weeks. Results: Forty-one patients were treated at 7 dose levels. The MTD was reached at the dose of 1,750 mg/m² for gemcitabine and 450 mg/m² for pemetrexed. Dose-limiting events were grade IV neutropenia, febrile neutropenia and treatment delay due to grade III hematological toxicities. One partial response in a pretreated patient with ovarian cancer was observed, while 4 other patients experienced stable disease. Conclusions: The biweekly administration of gemcitabine plus pemetrexed at the recommended MTDs is safe, well tolerated and demonstrates antitumor activity which merits further evaluation in phase II studies.

show abstract

Impact of PET-CT on initial staging and treatment of breast cancer

Cited by 3 publications

References 0 publications

Utility of 18-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG PET-CT) in Gallbladder Cancer: Experience from a Tertiary Care Hospital

Utility of 18-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG PET-CT) in Gallbladder Cancer: Experience from a Tertiary Care Hospital

Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET

A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors

Contact Info

Product

Resources

About